Rhumbline Advisers Cerevel Therapeutics Holdings, Inc. Transaction History

Rhumbline Advisers

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	SELL	$38.96 - $42.75 $599,204 - $657,495	-15,380 Reduced 14.9%	87,810 $3.59 Million
Q1 2024 May 09, 2024	BUY	$40.88 - $43.27 $363,545 - $384,800	8,893 Added 9.43%	103,190 $4.36 Million
Q4 2023 Feb 08, 2024	BUY	$20.27 - $42.44 $134,309 - $281,207	6,626 Added 7.56%	94,297 $4 Million
Q3 2023 Nov 09, 2023	SELL	$20.26 - $31.91 $12,095 - $19,050	-597 Reduced 0.68%	87,671 $1.91 Million
Q2 2023 Aug 08, 2023	BUY	$23.9 - $35.38 $108,649 - $160,837	4,546 Added 5.43%	88,268 $2.81 Million
Q1 2023 May 11, 2023	BUY	$22.82 - $35.32 $90,367 - $139,867	3,960 Added 4.96%	83,722 $2.04 Million
Q4 2022 Feb 14, 2023	BUY	$25.35 - $31.96 $256,491 - $323,371	10,118 Added 14.53%	79,762 $2.52 Million
Q3 2022 Nov 10, 2022	BUY	$25.5 - $41.42 $185,563 - $301,413	7,277 Added 11.67%	69,644 $1.97 Million
Q2 2022 Aug 11, 2022	BUY	$20.62 - $37.15 $439,659 - $792,112	21,322 Added 51.95%	62,367 $1.65 Million
Q1 2022 May 12, 2022	BUY	$23.5 - $35.38 $101,332 - $152,558	4,312 Added 11.74%	41,045 $1.44 Million
Q4 2021 Feb 10, 2022	SELL	$29.21 - $44.64 $1,489 - $2,276	-51 Reduced 0.14%	36,733 $1.19 Million
Q3 2021 Nov 12, 2021	BUY	$21.26 - $38.85 $181,560 - $331,779	8,540 Added 30.24%	36,784 $1.09 Million
Q2 2021 Aug 05, 2021	BUY	$12.56 - $29.69 $354,744 - $838,564	28,244 New	28,244 $724,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.